Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline Consumer Healthcare (GSKCH) has introduced 2mg and 4mg Nicorette mini Lozenge in the US following a supply shortage.
Subscribe to our email newsletter
Nicorette mini Lozenge, a mini-sized stop-smoking lozenges, can double smokers’ chances of quitting and it comes in a discreet pocket-size vial so smokers can have it on hand to help address craving and withdrawal symptoms associated with quitting smoking.
In February 2014, the company voluntarily recalled all nicotine lozenges from warehouses and distributors manufactured at a site in Aiken after manufacturing issues affecting some batches were detected.
The company said that in some cases, the lozenges were larger or smaller than its manufacturing standards.
Production of Nicorette mini Lozenge has resumed after a comprehensive assessment and complex testing process to correct manufacturing issues and improve quality measures.
GlaxoSmithKline Consumer Healthcare Wellness & Skin Health Brands marketing director Sue Kelsey said: "The safety and well-being of our consumers is our number one priority and we did not compromise on the somewhat lengthy corrective actions that needed to be taken.
"We understand what a life-changing event stopping smoking can be and, at the same time, how incredibly difficult it can be to get there.
"For those looking for help, we hope that the return to market of Nicorette mini Lozenge and our online information can help to provide the tools and inspiration to get smokers towards their goals."
The company’s other FDA-approved nicotine replacement therapy (NRT) products include Nicorette gum and NicoDerm CQ.